Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fibrogen Inc CS 409 ILLINOIS STREET SAN FRANCISCO CA 94158 USA

www.fibrogen.com P: 415-978-1200 F: 415-978-1902

Description:

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 97,220
Enterprise Value, $K 76,940
Shares Outstanding, K 98,771
Annual Sales, $ 147,750 K
Annual Net Income, $ -284,230 K
Last Quarter Sales, $ 27,140 K
Last Quarter Net Income, $ -56,230 K
EBIT, $ -281,810 K
EBITDA, $ -276,940 K
60-Month Beta 0.70
% of Insider Shareholders 2.39%
% of Institutional Shareholders 72.71%
Float, K 96,410
% Float 97.61%
Short Volume Ratio 0.43

Growth:

1-Year Return -93.78%
3-Year Return -95.59%
5-Year Return -98.00%
5-Year Revenue Growth -30.62%
5-Year Earnings Growth -146.60%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.57 on 02/26/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -2.55
EPS Growth vs. Prev Qtr -9.62%
EPS Growth vs. Prev Year 18.57%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

FGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -51.00%
Profit Margin % -192.37%
Debt/Equity -0.39
Price/Sales 0.72
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.87
Interest Coverage -17.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar